FDA launches “Bad Ad Program” to detect misleading drug ads

The FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading. The program will be rolled out in three phases. In Phase 1, DDMAC will engage healthcare providers at specifically-selected medical conventions and partner with specific medical societies to distribute educational materials. Phases 2 and 3 will expand the FDA’s collaborative efforts and update the educational materials developed for Phase 1.

Health care professionals are encouraged to report a potential violation in drug promotion by sending an email to [email protected] or calling (877) RX-DDMAC. Reports can be submitted anonymously; however, the FDA encourages providers to include contact information so that DDMAC officials can follow-up, if necessary.

For more information visit www.fda.gov/badad.